Dasatinib dose management for the treatment of chronic myeloid leukemia

The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia

(2018) SALIH AKSU   UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034

(2016) Neil P. Shah et al.   AMERICAN JOURNAL OF HEMATOLOGY

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

(2016) Delphine Rea et al.   BLOOD

Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia

(2016) Masahiro Imamura   Geriatrics & Gerontology International

Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study

(2016) Michael Lauseker et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

(2016) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature

(2016) Caroline Jamison et al.   ONCOLOGY RESEARCH

ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib

(2016) Géraldine Dessilly et al.   PHARMACOGENOMICS

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission

(2015) Harry P. Erba   AMERICAN JOURNAL OF HEMATOLOGY

Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia

(2015) Yoji Ishida et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib

(2015) Jose Francis et al.   MEDICAL ONCOLOGY

Milestones and Monitoring

(2015) Alessandro Morotti et al.   Current Hematologic Malignancy Reports

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

(2015) Koji Sasaki et al.   Lancet Haematology

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

(2015) Jun Imagawa et al.   Lancet Haematology

How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia

(2014) David M. Ross et al.   BRITISH JOURNAL OF HAEMATOLOGY

Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor Therapy

(2014) Alfonso Quintás-Cardama et al.   Clinical Lymphoma Myeloma & Leukemia

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

(2014) Henrik Hjorth-Hansen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib

(2014) Carla Boquimpani et al.   LEUKEMIA & LYMPHOMA

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib

(2013) Paul La Rosée et al.   ANNALS OF HEMATOLOGY

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective

(2013) Ishan Hirji et al.   Health and Quality of Life Outcomes

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

(2011) F. Efficace et al.   BLOOD

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

(2010) Fabio P. S. Santos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL